Milestone
Philadelphia's Acuity Pharmaceuticals has planned for this fall the first-ever human tests of RNA interference (RNAi), in which small pieces of RNA are used to turn off disease-causing genes. Acuity aims to test RNAi's mettle as a treatment for a severe form of age-related macular degeneration, which is a common cause of adult blindness.
Follow-Up
To read the entire article you must log in:
Most of our content — all daily news, blogs, and videos — is free. Magazine stories are paid. To read this story, you must have a subscription or you must use a reading credit. Registration to Technology Review is free and entitles registrants to three free reading credits.
Manufacturing in the United States is in trouble. That's bad news not just for the country's economy but for the future of innovation.
Our list of the 50 most innovative companies, including the following:
On Twitter
Become a Fan on Facebook
Subscribe to the Feed